Surgical Aspects of Decompression Craniectomy in Malignant Stroke: Review

Klaus Zweckberger\textsuperscript{a} Eric Juettler\textsuperscript{c} Julian Bösel\textsuperscript{b} W. Andreas Unterberg\textsuperscript{a}

Departments of \textsuperscript{a}Neurosurgery and \textsuperscript{b}Neurology, University Heidelberg, Heidelberg, and \textsuperscript{c}Department of Neurology, University Ulm, Ulm, Germany

\section*{Abstract}
\textbf{Background:} Space-occupying malignant stroke of the middle cerebral artery (MCA) is associated with a high mortality rate of up to 80\% under conservative treatment. Although there is convincing evidence that decomposition craniectomy can significantly reduce mortality rate and improve neurological outcome in young patients (<60 years), many surgeons are still hesitant to recommend hemicraniectomy for stroke patients. \textbf{Summary:} This review addresses some major issues that appear to be an obstacle to decompression craniectomy, in particular, indicating surgery for patients >60 years or with infarcts of the dominant hemisphere. Furthermore, it emphasizes technical issues such as timing and size of the craniectomy, additional temporal lobectomy, and resection of the temporal muscle, as well as duraplasty and cranioplasty. According to the current literature, decompression craniectomy in older patients can increase survival without most severe disabilities, although, most survivors need assistance in most bodily needs. Involvement of the dominant hemisphere results in aphasia that might partly recover in younger patients, although, considering the neuropsychological deficits caused by infarctions of the non-dominant hemisphere, involvement of the dominant hemisphere does not pose as a contraindication for decompression craniectomy. Furthermore, there is convincing evidence that surgery should be performed within 48 h after the onset of symptoms and the size of the craniectomy should be at least 12 cm as a minimum. An additional lobectomy or the resection of the temporal muscle, however, can only be part of individual treatment options. Conceding the weak evidence, it is recommended to close the dura by some form of a duraplasty avoiding cerebrospinal fluid leakages or scarring between the cortex and the scalp leading to injuries during reimplantation of the bone-flap. Complications associated with decompression surgery (hemorrhages, infections, ‘sinking skin-flap syndrome’, cerebrospinal fluid leakages, hydrocephalus, seizures), with the infarction itself, or with those that occur during the ICU course (cardiac and pulmonary complications) appear acceptable and are mostly treatable, especially considering the fatal course of conservative treatment. \textbf{Key Message:} This review summarizes the current state of the literature about decompression craniectomy of patients with malignant stroke addressing, in particular, critical surgical issues, and thus, help surgeons to make decisions confidently for/or against performing surgery.

\section*{Key Words}
Middle cerebral artery infarction · Surgical decompression · Hemicraniectomy · Indications for surgery
Introduction

Space-occupying infarctions of the middle cerebral artery (MCA) that may also include parts of the anterior (anterior cerebral artery, ACA) or posterior (posterior cerebral artery, PCA) territories constitute up to 10% of all supra-tentorial strokes [1, 2] (fig. 1). Characteristically, this type of infarction is associated with substantial brain edema, brain shift, increased intracranial pressure (ICP), and thus, uncal or trans-tentorial herniation, finally leading to brain death [3–6]. Clinically, patients present symptoms including contralateral hemiplegia or hemiparesis, aphasia if the dominant hemisphere is affected, and head or eye deviation. Because of the development of excessive brain edema, patients deteriorate uniformly and rapidly within 2–5 days after onset of symptoms. Under standard conservative care, these space-occupying MCA infarctions are affiliated with a fatality rate of up to 80% [2, 3, 6]. Reflecting the fatal course of this type of infarction, the expression malignant stroke was coined [3]. While this type of infarction was considered not treatable but fatal for a long time, especially since the increasing number of patients more from the younger generation, further treatment options became necessary [3]. Decompression craniectomy is not a new idea and has been used as an individual treatment option in order to control extending brain edema and to improve cerebral perfusion pressure for many decades. Since the publication of prospective randomized trials (DECIMAL, HAMLET, DESTINY I, Zhao et al., DESTINY II, HeADDFIRST) [7–13, 26] showing a significant reduction in mortality rate and an improvement in neurological outcome, evidence for decompression craniectomy is growing. While it has consequently been implemented in the treatment of malignant stroke, many surgeons remain skeptical and often have several caveats indicating hemicraniectomy. In particular, and with respect to the neurological outcome, the age of the patient and involvement of the dominant hemisphere are critical issues. Furthermore, technical aspects such as the size of the craniectomy, performing an additional temporal lobectomy, or the use of different materials for the dura-plasty, as well as the timing of surgery itself, are broadly underestimated in many trials, and therefore, are set in the focus of this review, conceding that the body of evidence is weak in many critical issues.

Conservative Treatment

The primary aim of any treatment approach for acute space-occupying brain infarction constitutes the control over the excessive brain edema development and the improvement of cerebral perfusion pressure and oxygen tissue saturation. Most patients are stuporous or comatose and in order to prevent them from aspiration, intubation, sedation, and mechanical ventilation are frequently necessary [14]. While many physicians on neuro intensive care units support ICP monitoring in unconscious patients, it is still debatable whether an ICP-targeted therapy might improve outcome of stroke patients. Poca et al. could not prove any advantage of ICP monitoring in comparison to clinical examinations and CT scanning [15]. Medical treatment of cerebral edema mainly consists of osmotherapy with mannitol or hypertonic saline, sedation, and eventually hyperventilation, buffers, or hypothermia [16, 17]. It should, however, be considered that none of these treatment options have been investigated in randomized clinical trials, so far [18]. Direct comparison of equiosmolar doses of mannitol (20%) and hypertonic saline (23.4%) has shown comparable effects on cerebral blood flow (CBF) in positron emission tomography (PET), but unchanged cerebral blood volumes (CBV) [19]. Of note, this work did not confirm alleged fears of osmotic agents actually residing in the infarcted tissue and subsequently promoting edema development and mid-line shift. A recently published meta-analysis considering 112 patients of 5 trials describe an advantage for hypertonic therapy in comparison to mannitol in order to control elevated ICP with a mean difference of 2 mm Hg [20]. In general, more neurointensivists favor the use of hypertonic saline for a reduced frequency of rebound edema, less side effects, desired volume expansion, and a longer-lasting duration of therapeutic effects [21]. Furthermore, therapeutic hypothermia (33°) offers a neuro-
Surgical Aspects of Decompression Craniectomy in Stroke

**Surgical Treatment**

*Controlled Randomized Clinical Trials*

Based on the promising results of experimental research and nonrandomized clinical studies, meanwhile eight randomized controlled trials have been initiated. While the Turkish DEMITUR trial is completed, but still unpublished, and the HeMMI study (Hemicraniectomy for middle cerebral artery infarction) is still recruiting, six trials have been finalized (DECIMAL, HAMLET, DESTINY I, Zhao et al., DESTINY II, HeADDFIRST). In addition, a prospective pooled data analysis of DECIMAL, HAMLET, and DESTINY I has been performed including patients treated within 48 hours. With the exception of the HeADDFIRST trial, all these studies show a significant reduction in the mortality rate and improved outcome [7–10, 13].

The German DESTINY I study (Decompressive Surgery for the Treatment of Malignant Infarction of the Middle Cerebral Artery) included 32 patients from 18 to 60 years and an NIHSS score of >18 for the nondominant and >20 for the dominant hemisphere. On CT scans, two-thirds of the MCA territory and at least parts of the basal ganglia had to be involved. Patients were randomized within 12–36 h following the onset of symptoms. Patients who received surgical decompression craniectomy showed a significantly reduced 1-year mortality rate (18% vs. 53%; p = 0.03) and an improved neurological outcome in the Modified Rankin Score (mRS) after 180 days and after 1 year, respectively (mRS 2–3 (180 days): 47% vs. 27%; mRS 2–3 (1 year): 48% vs. 27%) [8].

The French DECIMAL study (Decompression Craniectomy in Malignant Middle Cerebral Artery Infarction) enrolled 38 patients younger than 55 years and with an NIHSS score >15. Patients were randomized to decompression surgery versus best medical treatment within 30 hours following stroke. The 1-year mortality rate was significantly reduced in surgically treated patients (25% vs. 78%; p = 0.0001) and modified Rankin Scores showed a nonsignificant trend of neurological improvement (mRS ≤3 (6 months): 25% vs. 5.6%; p = 0.18 and mRS ≤3 (1 year): 50% vs. 22.2%; p = 0.1). A comparison of outcomes according to non-dichotomized scores on the mRS differed significantly between the two groups at 6 and 12 months follow-up in favor for craniectomy (p = 0.011 and p = 0.0024, respectively) [9].

The Dutch HAMLET study (Hemicraniectomy after Middle Cerebral Artery Infarction with Life-threatening Edema Trial) recruited 64 patients between 18 and 60 years with an infarction including at least two-thirds of the MCA territory associated with space-occupying edema on CT scans. Randomization was performed within 96 hours after onset of symptoms, and thence, significantly later compared to the DECIMAL and DESTINY trials. As a secondary endpoint, mortality rate in the surgical group was not so significant after 1 year (22% vs. 59%; p = 0.002). Neurological outcome, however, could not be improved (mRS 4–6: 75% vs. 75%; mRS 5–6: 41% vs. 59%) after 1 year. A subgroup of patients who was operated within 48 hours, however, showed significant better neurological outcomes [7].

In the pooled analysis of the DESTINY I, DECIMAL, and HAMLET trials, 93 patients with an age ranging between 18 and 60 years, an NIHSS score >15, and an infarction size greater than two-thirds of the MCA territory on CT scans or an infarct volume of at least 145 cm³ on DWI scans, were randomized to decompression surgery or best medical treatment within 48 h after the onset of symptoms. Decompression craniectomy resulted in an absolute risk reduction of 50% for mortality, of 42% for mRS ≥4, and of 16% for mRS ≥3 after 12 months. Seventy-five percent of surgically treated patients achieved an mRS of 0–4 (vs. 24% in the conservative treatment arm, p = 0.0001). 43% achieved an mRS of 0–3 (vs. 23%, p = 0.014), respectively [10].

Despite this convincing body of evidence derived from the European studies, these results could not be confirmed in the currently published HeADDFIRST trial. Among the 4,909 patients screened from 2000 to 2002, finally only 24 patients were randomized in a medical treatment (n = 10) or a medical treatment plus decompression surgery (n = 14) group. Acute mortality (21 days after stroke) was reduced in surgically decompressed patients by 19% (21% medical treatment plus surgery vs. 40% medical treatment, p = 0.39), but this difference has
already been redeemed within 180 days (36% vs. 40%). Furthermore, there was no significant effect on neurological outcome 180 days after stroke. Authors explained these differences, as well as the small fatality rate in conservatively treated patients, compared to the European trials mainly based on the randomization process and the study protocol, having ‘stricter’ inclusion criteria identifying patients on risk for excessive edema, incorporating older patients (up to 75 years), and having a wider time window for decompression surgery (until 96 h). These conclusions, however, contradict the discoveries derived from the HAMLET and other European trials [7–10, 13].

Despite the convincing and promising results from the European trials, and partly since the contradicting results from the HeADDFIRST trial [26], many surgeons are still hesitant to indicate decompression craniectomy apparently under the conception that reducing the mortality rate may result in an increased amount of severely disabled and dependent patients in which quality of life seems unacceptably poor. The remainder of this review therefore focuses on some of the most important obstacles that come in the way of performing a decompression surgery for patients with malignant stroke.

Timing for Decompression Surgery
Timing of surgery seems to be an important factor for mortality and neurological outcome. There are two studies explicitly emphasizing this issue. Already in 1998, Schwab et al. examined the effect of early (21 h) versus late decompression craniectomy (39 h) in 63 patients showing a decreased mortality rate (16% vs. 34%) and a reduced rate of herniation (13% vs. 75%) in early treated patients, as well as a shorter time on the ICU (7.4 vs. 13.3 days) [27]. In a retrospective trial on 21 patients, Wang et al. showed the effect of an early decompression craniectomy versus late decompression (<24 h vs. <24 h after onset of symptoms). The mortality rate was equal, but severe disability could be reduced in early treated patients [28]. Both in the DECIMAL and DESTINY trials, decompression craniectomy was performed within 43 or 36 h after the onset of symptoms, respectively [8, 9], resulting in reduced early and long-term mortality rates and improved neurological outcomes. The HAMLET trial, allowing decompression surgery up to 96 h, did show a significant reduction in the mortality rate after one year or improved neurological outcome, at least not in patients treated after 51 h of onset of symptoms [7]. Several retrospective studies have included patients who have already shown uncal hernation and one dilated pupil. Marmotom et al. described in a nonrandomized study on 24 patients (14 were treated by decompression surgery) a mortality rate of 57% in surgically treated patients, and 0% in patients who received conservative treatment, showing that late decompression surgery after onset of herniation is not beneficial [29]. Similar effects were seen in the prospective study of Malm et al. [30]. Out of 30 enrolled patients 14 showed signs of herniation (dilated pupil), and the time point of surgery varied broadly from 13 to 235 h after stroke [25]. Likewise, these results are supported by a prospective study of Kilincer et al. identifying signs of herniation as a prognostic factor for poor outcome [31], and by several retrospective trials [32, 33, 34]. Furthermore, in the studies of Skoglund et al. (n = 18) and Chung et al. (n = 24) 67 and 100% of patients, respectively, showed signs of herniation, leading to worse neurological outcomes compared to the results of the DECIMAL and DESTINY trials [8, 9, 35, 36].

On the other hand, Cho et al. described in a small cohort of 12 patients a positive effect of ultra-early decompression craniectomy performed within 6 h after the onset of symptoms. The acute mortality rate was 8.3%, compared to 36.7% for delayed decompression surgery, and 80% for conservative treatment [37].

While there are reservations that very early decompression surgery might potentially be unnecessary, it is clear that decompression surgery beyond 48 h after the onset of symptoms is less effective, or may even be ineffective in order to reduce mortality and to improve neurological outcome, especially when waiting until signs of herniation are present.

Size of the (Hemi-)Craniectomy
As a matter of principle, hemicraniectomy and durotomy are performed in order to allow the infarcted hemisphere to swell and to avoid further compression and damage of adjacent cortical structures and to prevent herniation. Besides the size of the craniectomy itself, osteoclastic temporal enlargement is particularly important to decompress the middle cranial fossa. A suboptimal size smaller than 12 cm in diameter has been described to cause additional cortical lesions leading to a decreased survival rate (55% vs. 80%) [38] (fig. 2). Most studies postulate a diameter of at least 12 cm as an absolute minimum [27, 30, 39–41]. Likewise in the prospective trials (DESTINY I, DECIMAL, HAMLET) and their pooled analysis, a diameter of at least 12 cm was claimed [7–10] (fig. 3).

Some smaller studies, however, describe even larger sizes of more than 14 cm in diameter [28, 42, 43] or including the superior sagittal sinus [44]. Walz et al. de-
scribed an acute mortality rate in the first week of only 11%. 91.6% of survivors showed moderate or slight disabilities and only 8.3% severe dependency after 14 months [42]. Furthermore, Park et al. emphasize the effect of an additional resection of the temporal muscle optimizing the decompressive effect of the craniectomy (>12 cm). 20% of the operated patients died. Although 60% of the survivors showed an mRS <4, 20% remained severely disabled and dependent (mRS ≥4) in a 6 months follow-up assessment [45].

In a recently published study, Chung et al. could demonstrate that a maximal size of decompression craniectomy (>14–16 cm or >399 cm²) versus a large size (>12 cm or 308 cm²) increases the ratio of a favorable outcome 3 months after stroke (mRS ≤3) and decreases the ratio of poor outcomes or deceased patients [36]. While there is growing evidence that large craniectomies (>14 cm in diameter) seem to predict favorable outcome, there is no evidence derived from clinical randomized prospective trials that an enlargement of the craniectomy including the superior sagittal sinus or of the resection of the temporal muscle are beneficial. Giving any recommendations these aspects should first be examined in clinical randomized prospective trials.

**Temporal Lobectomy**

Some studies describe the attempt to pull up the decompressive effect of the craniectomy and to prevent further brainstem compression by performing an additional temporal lobectomy. This issue, however, is not examined in clinical randomized trials. Greenwood, one of the first who has described surgery for brain infarction, reported successful outcomes in 6 out of 9 patients following craniectomy and resection of infarcted brain tissue [46]. Though there are some retrospective studies and case reports acknowledging successful anterior lobectomies [47], it has not been consistently shown yet that this procedure has beneficial effects on the mortality rate or on neurological outcome compared to patients with an adequately sized craniectomy alone [32, 42, 43]. In none of the prospective controlled randomized multi-center trials lobectomies were conducted (DECIMAL, DESTINY I, HAMLET) [7–9].

On the other hand, there are certain concerns regarding the risk of hemorrhages in resecting fragile infarcted brain tissue, particularly if the patients have been treated with aspirin, which is often part of the initial stroke management.

Based on the current literature and owing to the lack of evidence, it remains unclear if additional lobectomy might be beneficial. Giving any recommendation this issue should first be addressed in clinical randomized prospective trials.

**Duraplasty**

In order to achieve a maximal decompressive effect of the craniectomy, the opening of the dura is mandatory. To reduce the risk of cerebral spinal fluid (CSF) leakages, most neurosurgeons might advocate some form of dura closure. Considering the expansion of the underlying brain tissue, the use of a duraplasty seems to be necessary. Another objection to leaving the dura open are potential problems that might occur during subsequent cranioplas-
ty. Adhesions and scars formed between the cortex, the scalp, or the temporal muscle could induce injuries of the cortex and bleedings during the preparation for reinsertion of the bone flap. The literature suggests that different materials may be used for duraplasty, including artificial ones such as bio-design grafts or Gore-Tex®, as well as autologous ones, such as fascia lata or galea periosist.

As an alternative to the ‘classical duraplasties’ Gueresir et al. described on more than 300 patients a ‘rapid closer technique’ using haemostyptic materials (‘Surgicel’) in order to create a scarring layer between the cortex and the scalp not increasing the complication rate, especially for CSF leakages (<1%) or abscesses (<2.6%) [48]. Alternatively, the formation of such a layer may be done by the use of silicone or poly-tetra-fluoro-ethylene sheets [49, 50].

Nevertheless, no differences on complication rates or on the clinical outcome could be reported so far, conceding that there are no studies available comparing different materials in particular.

Cranioplasty – Reinsertion of the Bone Flap
Timing for reinsertion of the bone flap varies considerably between 6 weeks and 6 months. There is no study however, that examines the effect of timing on the clinical outcome of patients. In accordance with the available literature, timing does not influence complications, but there might be an advantage for early reinsertion (<3 months), especially with respect to the risk for infections [51–56]. Recently published studies reported an approximate overall complication rate of up to 35% [51, 52], 26% of patients had minor complications including seizures (15.6%) or subgaleal fluid collections (3.1%), and superficial wound infections (3.1%), whereas major complications (10.4%) encompass hydrocephalus (3.1%), transient neurological deficits (3.1%), and osteomyelitis (2.1%) [51]. Wachter et al. reported about a complication rate of 30% with 17.4% aseptic bone necrosis, 5% wound infections, 2.5% hematoma, 2.7% hygroma, and 1.7% unsatisfying cosmetic results [53]. In a large series of 239 patients, Walcott et al. described an overall complication rate of 24%. They could not find predicting factors such as age, location of the cranioplasty, presence of an intracranial device (like an ICP probe), bone flap preservation method, cranioplasty material, and time interval >90 days between initial craniectomy and cranioplasty [57]. On the other hand, re-operation was clearly identified as an independent risk factor [57]. Considering the dire outcome of conservative treatment affiliated with a fatality rate of 70–80%, these mostly minor complications appear acceptable, are usually easy to treat, and should not constitute an argument not to perform decompression craniectomy.

Age Limit
The pooled analysis of the three prospective trials (DECIMAL, DESTINY I, HAMLET) showed a significant reduction in mortality rate by almost 50% and a significant improvement in the clinical outcome in patients younger than 60 years. Furthermore, in a retrospective database analysis of 188 patients Uhl et al. showed encouraging effects for decompression craniectomy in space-occupying MCA infarctions in patients <50 years, but the results for older patients remained questionable [58]. Hence, it was doubtful for a long time if patients older than 60 years might also benefit from decompression craniectomy [7–10, 58].

Regardless of other factors, age is an independent predictor for poor outcome. In 2001, Holtkamp et al. assessed the effect of decompression craniectomy on the outcome of patients between 55 and 75 years of age. Even though they could show a reduction in mortality in the surgical group (33% vs. 75%), the neurological outcome was poor [39]. Their results were supported by several clinical series [31, 33, 34, 41–43, 58, 59]. In a review Arac et al. reported about 273 patients from 19 studies showing a mortality rate of 51% in the sub-group analysis of patients older than 60 years versus 21% in younger patients, associated with a significantly larger number of patients with poor neurological outcomes in the subgroup >60 years (81.8% vs. 33.1%) [60]. Although there are several studies indicating less beneficial effects for older patients, there was a dearth of controlled prospective randomized trials. A problem of most of these studies is that older patients were often operated much later and did often not receive maximal conservative treatment. The recently published prospective randomized controlled clinical multi-center DESTINY II trial investigated for the first time the effect of decompression craniectomy on older patients in an adequately powered randomized study [12, 61]. DESTINY II enrolled 112 patients older than 60 years (median age 70 years, range 61–82 years) within 48 h after onset of symptoms [61]. At the primary endpoint after 6 months, mortality rate was reduced in the hemicraniectomy group (33% vs. 70%). No patients, however, survived with an mRS 0–2, and only 7% in the surgical arm reached an mRS of 3 compared with 3% in the conservative arm. The rates for mRS of 4 were 32 and 15, respectively. Modified RS of 5 was more frequent in surgically treated patients (28% vs. 13%). At the secondary endpoint after 12 months hemi-
craniectomy still supports survival, although the total number of deaths has increased in both groups (43% vs. 76%, respectively). Overall, 38% of the surgically treated patients, compared with 16% of the conservatively treated ones, achieved an mRS ≤ 4. In conclusion, early hemi-
craniectomy increases the probability of survival, but most survivors will have substantial disabilities [12, 61]. Fur-
thermore, in a recently published prospective randomized
trial Zhao et al. reported slightly better results in a sub-
group analysis of patients older than 60 years who re-
ceived decompression craniectomy showing a reduced mortality rate (19% vs. 69%) and less patients with poor
neurological outcomes (mRS 4–5) [11].

In accordance with the available literature, there is
convincing evidence that decompression craniectomy
improves the chance for survival, also in patients older
than 60 years. An overwhelming number of patients,
however, remain dependent (mRS 4 or 5), and only few
achieve an mRS of 3. Especially the number of patients
remaining in complete dependency (mRS of 5) is consid-
erably high (20%) compared with younger patients (4%)
[10, 12, 61]. There is still a controversial discussion about
the acceptability of such a neurological outcome when the
alternative is death. Although, in many studies an age of
60 years distinguishes between old and young patients
with malignant MCA infarction, the physiological consti-
tution of the individual patient, and his/her will to accept
severe handicaps instead of being dead, especially be-
tween 60 and 70 years, varies considerably. Therefore, it
is problematic to state a cut-off age of 60 years. Instead, it
is recommendable to discuss potential chances of surgery,
but also associated risks for poor outcome with the pa-
tients’ relatives and to explore the potential attitude of the
patient towards a life-saving procedure potentially asso-
ciated with severe disabilities. Nevertheless, many people
have reservations about a life-saving surgical procedure
for the price of being highly disabled and dependent. In a
population-based epidemiological study, 312 adults were
surveyed presenting a scenario of space-occupying MCA
infarction. Only 2% favored surgical intervention, 58%
were uncertain, and 39% were opposed to surgery. The
number of individuals opting for surgery increased in
better scenarios. If a poor outcome (mRS 4 or 5) was an-
ticipated, only 1 or 6% favored surgery, respectively [62].

Infarction of the Dominant Hemisphere
Especially with respect to the patients’ neurological
outcome it is still under debate whether decompression
craniectomy of the dominant hemisphere is recommend-
able. The impact of the dominant hemisphere is not suf-
ficiently considered in available studies of malignant
MCA infarction, and moreover, most studies include a
mixture of dominant and nondominant stroke patients,
or even mention only the number of patients with apha-
sia. The present overview shows the rate of dominant-
hemispheric infarction represented in the literature:
Holtkamp et al. (both sides without differentiation) [39],
Skoglund et al. (17%) [35], Foerch et al. (19%) [33], Mar-
mattom et al. (22%) [29], Rabinstein et al. (24%) [59],
Robertson et al. (25%) [32], Harscher et al. (27%) [41],
Yao et al. (32%) [63], Weil et al. (36%) [64], Chen et al.
(37%) [34], Jüttler et al. (37%) [12], Jüttler et al. (38%) [8],
Hofmeijer et al. (38% aphasia) [7], Zhao et al. (38%) [11],
Wang et al. (38%) [28], Koh et al. (43%) [65], Walz et al.
(44%) [42], Malm et al. (47%) [30], and Kiphuth et al.
(57%) [66], Vahedi et al. (60% aphasia in the conservative
arm, and 55% in the surgical arm, as an outcome param-
eter) [10], Vahedi et al. (60% survivors with aphasia after
1 year) [9]. Only few studies found a difference in out-
come after malignant MCA infarction that is influenced
by the side of the lesion. The reason why most studies do
not find any differences in outcome according to the
hemisphere is the fact that most studies use the mRS as
the main outcome parameter, where aphasia is not repre-
sented as a major parameter determining outcome. Apha-
sia is, however, the main, or often the only argument, why
decompressive surgery is more reluctantly addressed in
malignant stroke of the dominant hemisphere. Patients
nevertheless have a chance for language recovery. Young
age and early decompression surgery in patients with ma-
lignant dominant stroke have been identified as predic-
tors for language recovery, conceding that this might take
several months or even years and might be incomplete
[67]. While the recovery of language is modulated by sev-
eral factors including type, intensity, and timing of the
intervention or the severity of the initial presentation, the
anatomical regions for recovery are less clear [68–71]. A
growing body of evidence originating from transcranial
magnet stimulation studies (TMS) shows functional re-
organization of language in aphasic patients [72]. While
it is broadly assumed that shifting of functional language
regions to the nondominant hemisphere might establish
the foundation for recovery, current fMRI studies, how-
ever, demonstrate that patients with normal or close-to-
normal language functions at least 1 year after stroke
show a return to typical fMRI activation patterns when
compared to the results of fMRI data obtained in previous
studies that included healthy controls and comparable
language tasks [73, 74]. Reorganization of language func-
tions by shifting to the right hemispheric brain regions
was shown to be a less effective mode of language function recovery [73–75].

Though it might be problematic to indicate decompression craniectomy in older patients considering aphasia, involvement of the dominant hemisphere does not pose a contraindication for younger patients and should be performed as early as possible [67, 74]. Nevertheless, in two-thirds of involved patients, aphasia remained unchanged 12 months later and neuropsychological testing has revealed that 62% of the aphasics patients fulfilled the DSM-III-R criteria for depression 12 months after stroke. Furthermore, the prevalence of major depression increased within the first year from 11% to 33% [76]. These results emphasize the necessity for long-lasting neurological rehabilitation and neuropsychological care for aphasic patients.

Nevertheless, it must be pointed out that the severe neuropsychological deficits of nondominant hemispheric malignant infarcts might probably be least equally disabling as aphasia and depression is just as frequent in nondominant hemispheric infarcts. Except for studies on communication, ability studies on the quality of life or activities of daily living found no differences in any other domain between patients with malignant infarcts of the dominant and those of the nondominant hemisphere [12, 42, 77].

Complications

Complications following decompression craniectomy after malignant stroke must be differentiated in acute complications caused by the surgical procedure itself, complications occurring in the ICU, and delayed ones, for example, the development of a hydrocephalus or any associated ones with the cranioplasty. In fact, this aspect of decompression surgery for stroke has never been systematically assessed and all of the following are based on case series, case reports, or reports as part of adverse events listed in trials not focusing on complications in the first place. Although decompression craniectomy is an easy and safe procedure, the rare occurrence of severe complications might adversely affect the outcome of patients.

Complications following decompression craniectomy include hematomas, meningitis, and wound infections. Epidural hemorrhages (EDH) or parenchymal lesions were rarely reported and occurred only in exceptional cases, although, the number of cerebral spinal fluid (CSF) leakages remained indistinct [27, 38, 44, 77, 78]. The number of seizures has varied significantly and ranged from 11% up to 66%, although, it was not clearly shown whether their occurrence was a consequence of the surgical procedure or a more general phenomenon following stroke [44, 79]. In most studies, infection rates were not explicitly outlined. Investigations on trauma patients revealed an overall infection rate of about 11%, and a reabsorption rate of the bone flap of 7% following decompression craniectomy [80].

Notably, during the ICU treatment, cardiac and pulmonary complications may occur. Durga et al. have described a mortality rate of 36% as a consequence of cardiac disturbances [81]. Pneumonia, sepsis, and pulmonary embolism were frequent and often resulted in fatal complications during the ICU treatment [82].

The so-called ‘sinking skin flap syndrome’ might result in a paradoxical herniation, headaches, seizures, and focal neurological deficits [83–85]. In the DECIMAL trial, the authors have addressed this issue and suggested that the ‘sinking skin flap syndrome’ might be associated with smaller sizes of the craniectomy [9]. Furthermore, 62% of patients developed an extra-axial fluid collection, even though half of them had no ventricular drainage [86]. Delayed hydrocephalus, however, is a common phenomenon following stroke and has occurred in up to 30 or 47.8% of patients, respectively [87, 88]. The presence of pre-, or post-cranioplasty hydrocephalus might have negative effects on the neurological outcome and could be associated with a craniectomy limit <2.5 cm from the midline [89]. Early reinsertion of the bone flap might address this problem and help to prevent development of excessive axial fluid collections [86, 90].

Although the overall complication rate seems to be high, severe surgery-related complications are rare and often do not require revision. If they do, they are mostly well treatable (e.g., shunts for hydrocephalus), and thus appear acceptable, especially considering the fatal course associated with conservative treatment (80% mortality rate).

Summary and Conclusion

With reference to the available literature, there is convincing evidence that decompression craniectomy can significantly reduce the mortality rate and improve the neurological outcome in patients with malignant stroke. This applies especially to patients younger than 60 years who received an early (<48 h after onset of symptoms) and large (at least 12–14 cm) decompression craniectomy, whereas older patients have a less favorable outcome, although in older patients mortality and most se-
Cerebrovasc Dis 2014;38:313–323
DOI: 10.1159/000365864

References


